Macular Edema
Fluid accumulation in the outer layer of the MACULA LUTEA that results from intraocular or systemic insults. It may develop in a diffuse pattern where the macula appears thickened or it may acquire the characteristic petaloid appearance referred to as cystoid macular edema. Although macular edema may be associated with various underlying conditions, it is most commonly seen following intraocular surgery, venous occlusive disease, DIABETIC RETINOPATHY, and posterior segment inflammatory disease. (From Survey of Ophthalmology 2004; 49(5) 470-90)
Drugs by status
Approved for this indication (5)
Phase 4 trials (27)
Phase 3 trials (18)
Phase 2 trials (75)
- brimonidine
- alg-1001
- methylprednisolone
- abicipar pegol
- acetazolamide
- asp8232
- mecamylamine
- bevasiranib
- denufosol
- elamipretide
- tamsulosin
- imatinib
- beclomethasone
- ico-007
- interferon alpha-2a
- levosulpiride
- kvd001
- ocriplasmin
- opt-302
- bromocriptine
- pf-04523655
- pf-04634817
- lactose
- bi 1026706
- polivynilic alcohol
- sunitinib
- nesvacumab
- sf0166
- sirolimus
- aliskiren
- +45 more
Phase 1 trials (26)
Organizations
Organization Involved with Phase 4 Indications (119)
- Alimera Sciences
- Regeneron
- Bausch Health Companies
- Pfizer
- Novartis
- Allergan
- Bayer
- Bp Consulting, Inc
- GWT-TUD GmbH
- LUTRONIC Corporation
- Mallinckrodt
- Ocular Therapeutix, Inc.
- Southeast Clinical Research Associates, LLC
- Tampa Bay Uveitis Center, LLC
- The EMMES Corporation
- National Eye Institute (NEI)
- Bay Area Retina Associates
- Cairo University
- California Retina Consultants
- Center For Excellence In Eye Care
- Ciusss de L'Est de l'Île de Montréal
- Dong-A University
- Gottfried Wilhelm Leibniz Universität Hannover
- Greater Houston Retina Research
- Indiana University
- Inje University
- Instituto de Olhos de Goiania
- King Khaled Eye Specialist Hospital
- Johns Hopkins University
- Korea University
- +89 more
Organization Involved with Phase 3 Indications (66)
- Serono
- Roche
- Bausch & Lomb
- Kowa
- Mylan
- Ampio Pharmaceuticals. Inc.
- Santen Inc.
- Chengdu Kanghong Biotech Co.,Ltd.
- Chromaderm, Inc.
- Clearside Biomedical, Inc.
- Rudolf Foundation Clinic
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- National Institutes of Health (NIH)
- Shahid Beheshti University of Medical Sciences
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Maastricht University
- Chang Gung University
- Changhai Hospital
- Joslin Diabetes Center
- Jaeb Center for Health Research
- Kaohsiung Medical University
- King Saud University
- Marashi Eye Clinic
- Radboud University
- Retina Macula Institute
- Retina Specialists, PC
- Rush Eye Associates
- University of Groningen
- University of Heidelberg
- University of Melbourne
- +36 more
Organization Involved with Phase 2 Indications (110)
- Abbott
- Astellas
- Adverum Biotechnologies, Inc.
- Merck
- CoMentis
- Alcon
- Allegro Ophthalmics, LLC
- Aerie Pharmaceuticals
- Aerpio Therapeutics
- Eyegate Pharmaceuticals, Inc.
- GlaxoSmithKline
- KalVista Pharmaceuticals, Ltd.
- Opthea Pty Ltd.
- Regenxbio Inc.
- Sanwa Kagaku Kenkyusho Co., Ltd.
- SciFluor Life Sciences, Inc.
- Taiwan Liposome Company
- South Coast Retina Center; Carson, McBeath, Boswell, Inc.
- iCo Therapeutics Inc.
- Boehringer Ingelheim
- Mid-Atlantic Retina Consultations, Inc.
- Quark Pharmaceuticals
- Stealth BioTherapeutics Inc.
- Sierra Eye Associates
- Universidad Nacional Autonoma de Mexico
- Hanscom, Thomas, M.D.
- Jumper, J. Michael, M.D.
- Baylor University
- Case Western Reserve University
- University of London
- +80 more
Organization Involved with Phase 1 Indications (22)
- Daiichi Sankyo
- River Vision Development Corporation
- Sunshine Lake Pharma Co., Ltd.
- SurModics, Inc.
- Molecular Partners AG
- Retina Research Foundation
- Kresge Eye Institute
- Ophthalmic Consultants of Boston
- Tufts University
- University of Miami
- Vitreous -Retina- Macula Consultants of New York (VRMNY)
- Illinois Retina and Eye Associates
- University of Mannheim
- Retina Vitreous Associates Beverley Hills, California
- SARcode Bioscience
- VitreoRetinal Surgery, PA
- Washington University in St. Louis
- Fountain Medical Development Co., Ltd.
- Sesen Bio
- UNITY Biotechnology
- Targeted Therapy Technologies, LLC
- MingSight-Relin Pharmaceuticals Co., Ltd.
Organization Involved with Other Experimental Indications (45)
- Intuor Technologies, Inc.
- Kala Pharmaceuticals, Inc.
- OD-OS GmbH
- PolyPhotonix Medical
- Retina Research Institute, LLC
- Fondazione G.B. Bietti, IRCCS
- Brian Burke, MPH
- Narayana Nethralaya
- Alexandria University
- Barnes Retina Institute
- Eye Clinic Medic Zuljan Jukic
- Federal University of Health Science of Porto Alegre
- Federal University of Rio Grande do Sul
- Mashhad University of Medical Sciences
- Los Angeles Biomedical Research Institute
- McMaster University
- Norwegian University of Science and Technology
- Neon Hospital
- Ondokuz Mayıs University
- Retina Clinic, Sao Paulo, Brazil
- University of Oklahoma
- University of Southern Denmark
- Wake Forest University
- West Virginia University
- University of Zagreb
- Mayo Clinic
- Illinois Retina Associates
- Mie University
- Renal Research Institute
- Retina Associates, Kansas City
- +15 more